{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'filling in the PSS questionnaire,', 'blood samples for serum biomarkers.', 'During the postdiscontinuation period, information about date of disease progression, death,', 'adverse events, subsequent anticancer systemic therapy, radiotherapy, or surgical intervention will', 'be collected.', 'In case of disease progression and the need for second-line anticancer therapy, propranolol may be', 'continued beyond first-line progression if the drug is well tolerated and there are other indications to', 'continue -adrenergic blockade. It may be also replaced by other \u00df-blocker, if necessary. Cessation of', 'propranolol therapy should be gradual.', '6.6.4 Unscheduled Visits or Assessments', 'If the investigator determines that a subject should be monitored more frequently or with additional', 'laboratory parameters assessments than indicated by the protocol-defined visit schedule,', 'unscheduled visits or assessments are permitted. Unscheduled visits for radiographic evaluations are', 'allowed at any time as clinically indicated.', '7. Adverse Events', '7.1 Adverse Events Definitions', 'An adverse event (AE) is the development of an undesirable medical condition or the deterioration of', 'a pre-existing medical condition during treatment. However, it does not necessarily have to have a', 'causal relationship with this treatment.', 'A Serious Adverse Event (SAE) is an adverse event occurring during any phase of the study and at any', 'dose of the investigational product which fulfils one or more of the following criteria:', 'results in death,', 'is life-threatening (it refers to an event in which the patient was at risk of death at the time of', 'the event),', 'requires inpatient hospitalization or prolongation of existing hospitalization,', 'results in persistent or significant disability/incapacity.', '7.2 Expected Adverse Events', '7.2.1 Expected Adverse Events for Sunitinib', 'Adverse reactions related to sunitinib are listed below by system organ class and frequency.', 'Frequencies are defined as: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000', 'to <1/100); rare (> 1/10,000 to <1/1,000); very rare (<1/10,000); Frequency not known (cannot be', 'estimated from the available data).', 'The following undesired events, listed by body system, have been reported:', 'Page 34 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Blood and lymphatic system disorders', 'Very common: neutropoenia, thrombocytopenia, anaemia, leucopoenia.', 'Common: lymphopoenia.', 'Uncommon: pancytopenia.', 'Rare: thrombotic microangiopathy.', 'Immune system disorders', 'Uncommon: hypersensitivity.', 'Rare: angioedema.', 'Endocrine disorders', 'Very common: hypothyroidism.', 'Uncommon: hyperthyroidism.', 'Rare: thyroiditis.', 'Infections and infestations', 'Common: viral infections, respiratory infections, abscess, fungal infections, urinary tract infection,', 'skin infections, sepsis.', 'Uncommon: necrotising fasciitis, bacterial infections.', 'Metabolism and nutrition disorders', 'Very common: decreased appetite.', 'Common: dehydration, hypoglycaemia.', 'Rare: tumour lysis syndrome.', 'Psychiatric disorders', 'Very common: insomnia.', 'Common: depression.', 'Nervous system disorders', 'Very common: dizziness, headache, taste disturbance.', 'Common: neuropathy peripheral, paraesthesia, hypoaesthesia, hyperaesthesia.', 'Uncommon: cerebral haemorrhage, cerebrovascular accident, transient ischaemic attack.', 'Rare: posterior reversible encephalopathy syndrome.', 'Eye disorders', 'Common: periorbital oedema, myelid oedema, lacrimation increased.', 'Cardiac disorders', 'Common: myocardial ischemia, ejection fraction decreased.', 'Uncommon: cardiac failure congestive, myocardial infarction, cardiac failure, cardiomyopathy,', 'pericardial effusion, ECG QT prolonged.', 'Rare: left ventricular failure, torsade de pointes.', 'Vascular disorders', 'Very common: hypertension.', 'Common: deep vein thrombosis, hot flush, flushing.', 'Uncommon: tumour haemorrhage.', 'Respiratory, thoracic and mediastinal disorders', 'Very common: dyspnoea, epistaxis, cough.', 'Common: pulmonary embolism, pleural effusion, haemoptysis, dyspnoea exertional, oropharyngeal', 'pain, nasal congestion, nasal dryness.', 'Uncommon: pulmonary haemorrhage, respiratory failure.', 'Page 35 of 60']\n\n###\n\n", "completion": "END"}